DaVita Inc. (DVA): Price and Financial Metrics

DaVita Inc. (DVA): $121.11

1.26 (+1.05%)

POWR Rating

Component Grades














  • DVA scores best on the Growth dimension, with a Growth rank ahead of 94.12% of US stocks.
  • The strongest trend for DVA is in Stability, which has been heading up over the past 48 weeks.
  • DVA ranks lowest in Momentum; there it ranks in the 30th percentile.

DVA Stock Summary

  • Davita Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 96.53% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 12.67 for Davita Inc; that's greater than it is for 95.33% of US stocks.
  • Davita Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 20.98%, greater than the shareholder yield of 89.01% of stocks in our set.
  • Stocks that are quantitatively similar to DVA, based on their financial statements, market capitalization, and price volatility, are NXST, AMCX, KOP, LAMR, and ACHC.
  • DVA's SEC filings can be seen here. And to visit Davita Inc's official web site, go to www.davita.com.

DVA Valuation Summary

  • In comparison to the median Healthcare stock, DVA's price/sales ratio is 68.42% lower, now standing at 1.2.
  • DVA's EV/EBIT ratio has moved up 6.3 over the prior 243 months.
  • Over the past 243 months, DVA's price/sales ratio has gone up 0.1.

Below are key valuation metrics over time for DVA.

Stock Date P/S P/B P/E EV/EBIT
DVA 2021-08-31 1.2 10.7 15.9 17.0
DVA 2021-08-30 1.2 10.8 15.9 17.1
DVA 2021-08-27 1.2 10.7 15.9 17.0
DVA 2021-08-26 1.2 10.7 15.8 17.0
DVA 2021-08-25 1.2 10.7 15.9 17.0
DVA 2021-08-24 1.2 10.8 16.0 17.1

DVA Growth Metrics

  • The 3 year revenue growth rate now stands at -19.73%.
  • Its year over year price growth rate is now at 45.14%.
  • Its 2 year revenue growth rate is now at 14.54%.
Over the past 15 months, DVA's revenue has gone up $79,295,000.

The table below shows DVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 11,565.9 1,801.561 863.67
2021-03-31 11,529.37 1,772.951 771.452
2020-12-31 11,550.6 1,979.028 773.642
2020-09-30 11,543.87 2,174.76 844.74
2020-06-30 11,523.88 2,332.743 829.336
2020-03-31 11,486.6 2,291.432 901.285

DVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DVA has a Quality Grade of B, ranking ahead of 78.65% of graded US stocks.
  • DVA's asset turnover comes in at 0.666 -- ranking 43rd of 80 Healthcare stocks.
  • NTRA, VCYT, and RDNT are the stocks whose asset turnover ratios are most correlated with DVA.

The table below shows DVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.666 0.314 0.078
2021-03-31 0.650 0.310 0.074
2020-12-31 0.651 0.308 0.077
2020-09-30 0.648 0.313 0.083
2020-06-30 0.643 0.310 0.082
2020-03-31 0.636 0.310 0.092

DVA Price Target

For more insight on analysts targets of DVA, see our DVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $143.11 Average Broker Recommendation 2 (Hold)

DVA Stock Price Chart Interactive Chart >

Price chart for DVA

DVA Price/Volume Stats

Current price $121.11 52-week high $136.48
Prev. close $119.85 52-week low $80.85
Day low $120.00 Volume 649,100
Day high $122.47 Avg. volume 680,921
50-day MA $126.33 Dividend yield N/A
200-day MA $117.84 Market Cap 12.69B

DaVita Inc. (DVA) Company Bio

DaVita Healthcare Partners delivers dialysis services to patients with chronic kidney failure and end stage renal disease. The company was founded in 1994 and is based in Denver, Colorado.

DVA Latest News Stream

Event/Time News Detail
Loading, please wait...

DVA Latest Social Stream

Loading social stream, please wait...

View Full DVA Social Stream

Latest DVA News From Around the Web

Below are the latest news stories about Davita Inc that investors may wish to consider to help them evaluate DVA as an investment opportunity.

DaVita Kidney Care Names New Chief Nursing Officer

During Nephrology Nurses Week, DaVita Kidney Care begins a new chapter for its nursing program by announcing Tina Livaudais as the kidney care provider's chief nursing officer (CNO). Livaudais most recently served as vice president of clinical services for the national hospital services group, overseeing more than 4,600 DaVita teammates.

Yahoo | September 16, 2021

DaVita Inc. Consensus Indicates Potential 16.3% Upside

DaVita Inc. found using ticker (DVA) now have 9 analysts covering the stock. The analyst consensus points to a rating of ''Hold''. The range between the high target price and low target price is between 207 and 113 with the average target price sitting at 143.11. With the stocks previous close at 123.05 this would indicate that there is a potential upside of 16.3%. The day 50 moving average is 128.99 and the 200 day MA is 119.36. The market cap for the company is $13,050m. Visit the company website at: /> [stock_market_widget type="chart" symbol="DVA" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis ...

DirectorsTalk | September 14, 2021

Warren Buffett's Largest Healthcare Stock Investment

There are several healthcare companies in Berkshire Hathaway's portfolio, but only one in its top 10 holdings.

Yahoo | September 10, 2021

DaVita Announces Dr. Gregory Moore to Join its Board of Directors

DaVita Inc. announced today that its Board of Directors appointed a new independent director, Gregory Moore, M.D., Ph.D., to join the Board, effective Sept. 9, 2021.

Yahoo | September 9, 2021

Miromatrix Welcomes Dr. John Barry as Vice President of Research and Development

EDEN PRAIRIE, Minn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced the hiring of Dr. John Barry as Vice President of Research and Development. Dr. Barry will be leading the activities for the development of the Company's transplantable liver and kidney programs including the use of a bio-engineered liver in an

Yahoo | September 9, 2021

Read More 'DVA' Stories Here

DVA Price Returns

1-mo -8.55%
3-mo -0.18%
6-mo 11.35%
1-year 43.09%
3-year 73.21%
5-year 82.12%
YTD 3.16%
2020 56.47%
2019 45.80%
2018 -28.78%
2017 12.54%
2016 -7.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9846 seconds.